LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Strona główna・Stock List・United Therapeutics Corp

United Therapeutics Corp

Closed

Sector Healthcare

373.77 -0.06

Buy Sell

Overview

Share price change

24h

Current

Min

373.55

Max

375.61

Key metrics
By Trading Economics
Income	31M 309M
Sales	34M 749M
P/E Sector Avg	16.47 104.138
EPS	6.39
Profit margin	41.274
Employees	1,168
EBITDA	42M 427M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+6.83 upside

Market Stats
By TradingEconomics
Market Cap	447M 18B
Previous open	373.83
Previous close	373.77

News Sentiment

By Acuity

91%

12 / 389 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

352.58 / 375.175 Support & Resistance

United Therapeutics Corp Chart

Past performance is not a reliable indicator of future results.

Related News

7 paź 2024, 15:14 UTC

Major Market Movers

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

6.83% upside

12 Months Forecast

Average 399.55 USD 6.83%

High 600 USD

Low 302 USD

Based on 11 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to United Therapeutics Corp - Dist in the past 3 months.

Technical Score

By Trading Central

352.58 / 375.175Support & Resistance

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

12 / 389 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About United Therapeutics Corp

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.